Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
暂无分享,去创建一个
Itzhak Avital | S. Thorgeirsson | T. Roskams | L. Roberts | A. Barbour | V. Factor | J. Andersen | I. Avital | B. Blechacz | M. Komuta | M. Gillen | E. Conner | Tania Roskams | Lewis R Roberts | Snorri S Thorgeirsson | B. Spee | Jesper B Andersen | Bart Spee | Boris R Blechacz | Mina Komuta | Andrew Barbour | Elizabeth A Conner | Matthew C Gillen | Valentina M Factor
[1] J. Chung,et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas , 2005, Journal of Cancer Research and Clinical Oncology.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] Jung-Hwan Yoon,et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.
[5] Alphonse-E Sirica,et al. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. , 2008, World journal of gastroenterology.
[6] Tim Harris,et al. Gene and drug matrix for personalized cancer therapy , 2010, Nature Reviews Drug Discovery.
[7] T. Linné,et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[9] A. Tannapfel,et al. Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver , 2000, Gut.
[10] M. Aljiffry,et al. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. , 2009, World journal of gastroenterology.
[11] D. Berry,et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. , 2009, European journal of cancer.
[12] P. Philip,et al. Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Steven C Cunningham,et al. Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution , 2007, Annals of surgery.
[14] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[15] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[16] G. Gores,et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. , 2010, The Journal of molecular diagnostics : JMD.
[17] G. Gores,et al. New staging system and a registry for perihilar cholangiocarcinoma , 2011, Hepatology.
[18] Michael Gregor,et al. Serum and bile markers for cholangiocarcinoma. , 2004, Seminars in liver disease.
[19] C. Boni,et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial , 2009, British Journal of Cancer.
[20] P. Randazzo,et al. PTK6 Inhibits Down-regulation of EGF Receptor through Phosphorylation of ARAP1* , 2010, The Journal of Biological Chemistry.
[21] G. Gores,et al. Targeting IL-6 in Cholangiocarcinoma Therapy , 2007, The American Journal of Gastroenterology.
[22] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[23] S. Thorgeirsson,et al. An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer , 2010, Science Translational Medicine.
[24] Y. Nimura,et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. , 2006, The American journal of pathology.
[25] Mariano Provencio,et al. Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.
[26] Tara L. Kieffer,et al. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .
[27] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[28] Tim Harris. Does large scale DNA sequencing of patient and tumor DNA yet provide clinically actionable information? , 2010, Discovery medicine.
[29] P. Philip,et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[31] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .